Autolus Therapeutics (6A3A) Ratios
3 Followers
Autolus Therapeutics Ratios
DE:6A3A's free cash flow for Q2 2026 was $-25.98M. For the 2026 fiscal year, DE:6A3A's free cash flow was decreased by $-913.00K and operating cash flow was $-25.07M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.94 | 10.88 | 6.15 | 9.18 | 12.15 |
| Quick Ratio | 5.48 | 10.81 | 6.15 | 9.18 | 12.15 |
| Cash Ratio | 1.42 | 3.74 | 5.35 | 8.25 | 10.87 |
| Solvency Ratio | -0.68 | -0.60 | -0.76 | -0.74 | -1.45 |
| Operating Cash Flow Ratio | -3.86 | -3.40 | -3.25 | -2.42 | -4.13 |
| Short-Term Operating Cash Flow Coverage | -19.47 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 24.98M | $ 305.53M | $ 11.39M | $ 234.17M | $ 254.71M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.60 | 0.07 | 0.14 | 0.05 | 0.17 |
| Debt-to-Equity Ratio | 1.97 | 0.12 | 0.48 | 0.08 | 0.22 |
| Debt-to-Capital Ratio | 0.66 | 0.11 | 0.32 | 0.08 | 0.18 |
| Long-Term Debt-to-Capital Ratio | 0.60 | 0.00 | 0.00 | 0.00 | 0.13 |
| Financial Leverage Ratio | 3.31 | 1.83 | 3.37 | 1.64 | 1.29 |
| Debt Service Coverage Ratio | -4.71 | -25.24 | -3.48 | -14.88 | -119.94 |
| Interest Coverage Ratio | -7.66 | -25.98 | -3.99 | -16.05 | -127.04 |
| Debt to Market Cap | 0.54 | 0.00 | 0.00 | 0.00 | 0.13 |
| Interest Debt Per Share | 1.46 | 0.24 | 0.56 | 0.35 | 0.96 |
| Net Debt to EBITDA | -0.99 | 0.75 | 1.19 | 2.71 | 1.83 |
| Profitability Margins | |||||
| Gross Profit Margin | -27.83% | -1293.48% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -344.20% | -2379.34% | -9619.26% | -2254.79% | -9351.89% |
| EBITDA Margin | -331.21% | -2303.09% | -9232.63% | -2134.97% | -8790.64% |
| Operating Profit Margin | -372.45% | -2385.63% | -10583.10% | -2306.96% | -9314.80% |
| Pretax Profit Margin | -392.84% | -2165.36% | -12273.38% | -2398.56% | -9425.22% |
| Net Profit Margin | -381.40% | -2180.45% | -12272.26% | -2402.95% | -9429.06% |
| Continuous Operations Profit Margin | -381.40% | -2180.45% | -12272.26% | -2402.95% | -9429.06% |
| Net Income Per EBT | 97.09% | 100.70% | 99.99% | 100.18% | 100.04% |
| EBT Per EBIT | 105.48% | 90.77% | 115.97% | 103.97% | 101.19% |
| Return on Assets (ROA) | -48.92% | -28.19% | -55.51% | -30.36% | -35.04% |
| Return on Equity (ROE) | -161.79% | -51.64% | -186.93% | -49.83% | -45.35% |
| Return on Capital Employed (ROCE) | -54.58% | -33.44% | -54.35% | -32.19% | -37.23% |
| Return on Invested Capital (ROIC) | -51.54% | -33.30% | -53.53% | -31.83% | -36.80% |
| Return on Tangible Assets | -50.63% | -28.64% | -55.51% | -30.36% | -35.04% |
| Earnings Yield | -54.42% | -36.80% | -18.60% | -82.47% | -37.98% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.00 | 0.21 | 1.62 | 0.21 | 22.16 |
| Payables Turnover | 31.33 | 71.62 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 2.91 | 34.08 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.59 | 0.10 | 0.02 | 0.11 | 0.03 |
| Asset Turnover | 0.13 | 0.01 | 0.00 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 0.16 | 0.02 | 0.01 | 0.02 | 0.01 |
| Cash Conversion Cycle | 479.92 | 1745.50 | 225.06 | 1707.50 | 16.47 |
| Days of Sales Outstanding | 366.09 | 1739.88 | 225.06 | 1707.50 | 16.47 |
| Days of Inventory Outstanding | 125.49 | 10.71 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 11.65 | 5.10 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 491.57 | 1750.59 | 225.06 | 1707.50 | 16.47 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.07 | -0.81 | -0.84 | -1.18 | -1.64 |
| Free Cash Flow Per Share | -1.17 | -0.94 | -0.90 | -1.30 | -1.76 |
| Dividend Paid and CapEx Coverage Ratio | -10.45 | -5.92 | -13.25 | -10.36 | -13.31 |
| Capital Expenditure Coverage Ratio | -10.45 | -5.92 | -13.25 | -10.36 | -13.31 |
| Operating Cash Flow Coverage Ratio | -0.81 | -3.92 | -2.75 | -4.63 | -1.73 |
| Operating Cash Flow to Sales Ratio | -3.75 | -20.38 | -85.74 | -18.13 | -78.21 |
| Free Cash Flow Yield | -58.67% | -40.21% | -13.98% | -68.23% | -33.87% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.84 | -2.72 | -5.38 | -1.21 | -2.63 |
| Price-to-Sales (P/S) Ratio | 7.01 | 59.25 | 659.71 | 29.14 | 248.25 |
| Price-to-Book (P/B) Ratio | 2.97 | 1.40 | 10.05 | 0.60 | 1.19 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.70 | -2.49 | -7.15 | -1.47 | -2.95 |
| Price-to-Operating Cash Flow Ratio | -1.87 | -2.91 | -7.69 | -1.61 | -3.17 |
| Price-to-Earnings Growth (PEG) Ratio | -0.08 | 0.10 | 0.23 | 0.06 | 0.09 |
| Enterprise Value Multiple | -3.10 | -1.82 | -5.96 | 1.34 | -0.99 |
| Enterprise Value | 777.07M | 424.88M | 933.59M | -177.69M | 131.79M |
| EV to EBITDA | -3.10 | -1.82 | -5.96 | 1.34 | -0.99 |
| EV to Sales | 10.28 | 41.98 | 549.82 | -28.69 | 87.45 |
| EV to Free Cash Flow | -2.50 | -1.76 | -5.96 | 1.44 | -1.04 |
| EV to Operating Cash Flow | -2.74 | -2.06 | -6.41 | 1.58 | -1.12 |
| Tangible Book Value Per Share | 0.59 | 1.63 | 0.64 | 3.14 | 4.35 |
| Shareholders’ Equity Per Share | 0.67 | 1.67 | 0.64 | 3.14 | 4.35 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | -0.01 | 0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.28 | 0.04 | 0.01 | 0.07 | 0.02 |
| Net Income Per Share | -1.08 | -0.86 | -1.20 | -1.57 | -1.97 |
| Tax Burden | 0.97 | 1.01 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.14 | 0.91 | 1.28 | 1.06 | 1.01 |
| Research & Development to Revenue | 1.70 | 15.63 | 76.84 | 18.95 | 73.55 |
| SG&A to Revenue | 1.74 | 0.00 | 27.53 | 5.15 | 21.14 |
| Stock-Based Compensation to Revenue | 0.19 | 1.53 | 6.60 | 1.94 | 6.59 |
| Income Quality | 0.99 | 0.93 | 0.70 | 0.75 | 0.83 |
Currency in USD
